Incidentally detected PET-avid liver adenomatosis: MRI and 18F-FDG PET-CT findings

Ayşegül Öz1, Bedriye Koyuncu Sökmen1, Nagihan İnan1, Numan Cem Balço1, Yaman Tokat2
1Department of Radiology, İstanbul Bilim University School of Medicine, İstanbul, Turkey
2Department of General Surgery, İstanbul Bilim University School of Medicine, İstanbul, Turkey

Dear Editor,

Liver adenomatosis is a benign and rare tumor. It is defined as multiple hepatic adenomas (>4-10 lesions) in the normal liver parenchyma (1,2). Magnetic resonance imaging (MRI) is the primary method for the diagnosis of adenomas and is used in characterizing the subtypes. When incidental multiple liver lesions are detected and evaluated using positron emission tomography-computed tomography (PET-CT), the differential diagnosis of adenomas with malignancies and hypervascular metastasis is very difficult because adenomas can show 18-F-fluoro-2-deoxy-D-glucose (18F-FDG) uptake. Here we report the clinical and imaging findings of a PET-avid liver adenomatosis case.

A 35-year-old lactating woman was admitted to the general surgery department with abdominal pain. Blood tests showed no alterations. On abdominal ultrasound, multiple hyperechoic lesions were detected. Contrast-enhanced liver MRI was performed to characterize the lesions. Precontrast in-phase and out-of-phase sequences, T2-weighted images (WI), and pre- and postcontrast fat-suppressed (FS) T1-WI were evaluated. All lesions were isointense on in-phase images, hyperintense on T2-WI, and showed marked signal dropout on FS and out-of-phase sequences (Figure 1. a–e.). MRI confirmed multiple (10 lesions) fat-containing, slowly enhancing lesions, which were suggestive of liver adenomatosis. All lesions showed intense 18F-FDG uptake (Figure 2). The biggest lesion was 8 cm, with the standardized uptake value (SUVmax) of 7.6. Ultrasonography guided tru-cut biopsy revealed liver adenomas. Informed consent was obtained from all patients for MRI, PET-CT scans, and biopsy.

Liver adenomatosis is a very rare entity, and PET-avid liver adenomatosis is a very uncommon manifestation. Previous studies have found no correlation between liver adenomatosis and glycogen storage disease, steroid intake, or oral contraceptive use because it occurs in normal liver parenchyma (1,2). It affects both women and men, but some studies have reported female dominancy and oral contraceptive use (3,4). Our patient had no history of oral contraceptive use.

To our knowledge, this is the third case of PET-avid adenomatosis. All reported cases are HNF1-α mutated subtype and/or steatotic. There is no defined PET-positive inflammatory or telangiectatic subtype of liver adenomas.
(5). In our patient, all adenomas showed signal loss on the out-of-phase sequence and all were steatotic.

It is well known that focal fatty infiltrations and fat necrosis can be PET positive. The fatty infiltration of activated Kupffer cells leads to subacute inflammation, causing a higher SUV_max than the normal parenchyma (6,7). Thus, PET-CT can predict the HNF1-α subtype, which is the type of liver adenomas with the lowest risk for malignancy and hemorrhage (6).

Hepatic adenomas demonstrate various imaging findings based on their histologic subtypes and hemorrhagic components (6). MRI is the primary technique to evaluate the fat content and hemorrhage, which are very rare in metastasis, and is the best technique before biopsy to demonstrate steatotic changes, morphological characterization, and differential diagnosis of liver lesions (5,8). PET–MR scanning could also be taken into consideration for the identification of these lesions because it can determine both ¹⁸F-FDG uptake and lesion characterization.

**Informed Consent:** Informed consent was obtained from the patients who participated in this study.

**Peer-review:** Externally peer-reviewed.


**Conflict of Interest:** The authors have no conflict of interest to declare.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**REFERENCES**